Luca Sigalotti
Overview
Explore the profile of Luca Sigalotti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
1201
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Mastorci K, Montico B, Fae D, Sigalotti L, Ponzoni M, Inghirami G, et al.
Oncotarget
. 2016 Jun;
7(27):41913-41928.
PMID: 27248824
Mantle cell lymphoma (MCL) is an aggressive haematological malignancy in which the response to therapy can be limited by aberrantly activated molecular and cellular pathways, among which autophagy was recently...
12.
Mastorci K, Muraro E, Pasini E, Furlan C, Sigalotti L, Cinco M, et al.
PLoS One
. 2016 Apr;
11(4):e0153823.
PMID: 27123851
Mantle cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin's lymphoma with a still undefined etiology. Several lines of evidence are consistent with the possible involvement of peculiar microenvironmental stimuli sustaining...
13.
Maio M, Covre A, Fratta E, Di Giacomo A, Taverna P, Natali P, et al.
Clin Cancer Res
. 2015 Sep;
21(18):4040-7.
PMID: 26374074
Epigenetic regulation allows heritably modulating gene expression profiles without modifying the primary sequence of gDNA. Under physiologic conditions, epigenetic patterns determine tissue-specific gene expression landscapes, gene imprinting, inactivation of chromosome...
14.
Sigalotti L, Fratta E, Coral S, Maio M
Pharmacol Ther
. 2014 Jan;
142(3):339-50.
PMID: 24384533
Continuously improving knowledge of the fine mechanisms regulating cross-talk between immune cells, and of their multi-faceted interactions with cancer cells, has prompted the development of several novel immunotherapeutic strategies for...
15.
Sigalotti L, Fratta E, Parisi G, Coral S, Maio M
Methods Mol Biol
. 2013 Nov;
1102:481-99.
PMID: 24258994
Prognostic molecular markers are urgently needed for allowing to discriminate the clinical course of disease of melanoma patients, which is highly heterogeneous and unpredictable also within a specific clinicopathological stage...
16.
Fratta E, Sigalotti L, Covre A, Parisi G, Coral S, Maio M
Immunotherapy
. 2013 Oct;
5(10):1103-16.
PMID: 24088079
Malignant melanoma is a complex disease that arises and evolves due to a myriad of genetic and epigenetic events. Among these, the interaction between epigenetic alterations (i.e., histone modifications, DNA...
17.
Immunomodulatory activity of SGI-110, a 5-aza-2'-deoxycytidine-containing demethylating dinucleotide
Coral S, Parisi G, Nicolay H, Colizzi F, Danielli R, Fratta E, et al.
Cancer Immunol Immunother
. 2012 Nov;
62(3):605-14.
PMID: 23138873
Purpose: Pharmacologic DNA hypomethylation holds strong promises in cancer immunotherapy due to its immunomodulatory activity on neoplastic cells. Searching for more efficient DNA hypomethylating agents to be utilized to design...
18.
Whole genome methylation profiles as independent markers of survival in stage IIIC melanoma patients
Sigalotti L, Covre A, Fratta E, Parisi G, Sonego P, Colizzi F, et al.
J Transl Med
. 2012 Sep;
10:185.
PMID: 22950745
Background: The clinical course of cutaneous melanoma (CM) can differ significantly for patients with identical stages of disease, defined clinico-pathologically, and no molecular markers differentiate patients with such a diverse...
19.
Calabro L, Sigalotti L, Fonsatti E, Bertocci E, Di Giacomo A, Danielli R, et al.
J Cell Physiol
. 2011 Jul;
226(10):2595-600.
PMID: 21792917
No treatment prolongs the survival of malignant mesothelioma (MM) patients. Since MM elicits anti-tumor host's immune responses, immunotherapy represents a promising strategy for its control. Immunomodulatory antibodies against components of...
20.
Sigalotti L, Fratta E, Bidoli E, Covre A, Parisi G, Colizzi F, et al.
J Transl Med
. 2011 May;
9:78.
PMID: 21615918
Background: The prognosis of cutaneous melanoma (CM) differs for patients with identical clinico-pathological stage, and no molecular markers discriminating the prognosis of stage III individuals have been established. Genome-wide alterations...